Arcellx, Inc. (ACLX)
收市後：
| 前收市價 | 33.96 |
| 開市 | 33.90 |
| 買盤 | 34.57 x 1800 |
| 賣出價 | 34.79 x 800 |
| 今日波幅 | 33.06 - 35.40 |
| 52 週波幅 | 16.94 - 48.92 |
| 成交量 | |
| 平均成交量 | 443,044 |
| 市值 | 1.671B |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -4.22 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 50.70 |
Insider MonkeyShould You be Bullish on Arcellx (ACLX)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here. The fund advanced 9.22% (Institutional Shares) in the quarter compared to a 3.44% gain for the Russell 3000 Health Care Index (benchmark) and an 8.74% gain for the S&P 500 […]
BenzingaGilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate
Kite, a Gilead Sciences Inc company (NASDAQ: GILD), announced a global strategic collaboration to co-develop and co-commercialize Arcellx Inc's (NASDAQ: ACLX) lead late-stage product candidate, CART-ddBCMA, for relapsed or refractory multiple myeloma. Kite and Arcellx will jointly advance the CART-ddBCMA asset. Arcellx will receive an upfront payment of $225 million, a $100 million equity investment, and other potential contingent payments. The companies will share development, clinical trial, a
BenzingaAnalyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock
Needham initiated coverage on Arcellx Inc (NASDAQ: ACLX) with a Buy rating and a price target of $31. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for relapsed or refractory (r/r) multiple myeloma (MM). With two CAR-Ts already on the market - Bristol Myers Squibb Co's (NYSE: BMY) Abecma and Johnson & Johnson's (NYSE: JNJ) Carvykti, Arcellx is a fast follower. The analyst says that early data for CART-ddBCMA supports an efficacy profile in line with the
